Registry for early T1 bladder cancer after repeat bladder surgery
Part of Cancer, Kidney & urinary clinical trials.
This study follows people with newly diagnosed early bladder cancer (T1) to better understand outcomes and guide follow-up care. You may be able to join if your cancer is confirmed after a second look bladder procedure and scans show no spread.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of primary T1 (early) bladder cancer based on pathology
- Your diagnosis is confirmed again at a planned second bladder procedure (2nd look TURB)
- Scans show no lymph node spread and no distant spread (no metastasis)
- You agree to surgery and to follow the usual post-surgery care plan and follow-up visits
- If the cancer is still present on the second look, the bladder muscle (detrusor muscle) must be included in the pathology sample
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares the need for a second surgery for people with early-stage bladder cancer. It uses a simple urine test to see if the test can help decide whether a second operation is necessary, which could save some patients from an extra procedure.
This study tracks patients with early-stage bladder cancer after surgery (TURBT) to see how often the cancer returns and how it affects your daily life.
This trial checks whether a bladder scan and score (VI-RADS from MRI) can help doctors choose the right way to do a second look surgery for non-muscle-invasive bladder cancer. The goal is to reduce the chance of needing extra (“secondary”) resections while still catching important disease early.
This trial is testing whether a urine test for tumor DNA/RNA can help guide the decision for a second surgery in people with high-risk, non-muscle-invasive bladder cancer. It aims to see if the urine test can predict who needs the second surgery, potentially avoiding unnecessary procedures.
This trial studies if a urine test for tumor DNA can help decide when a second surgery is needed for early stage bladder cancer. It may reduce unnecessary procedures for some patients.
This trial tests STM-416, given around the time you have surgery to remove recurring bladder tumors, to see if it can reduce the chance the cancer comes back. It is for people with high-risk early bladder cancer (non–muscle-invasive) who have already had standard treatment and now need another TURBT.
Hear when a new T1 Urinary Bladder Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.